Drug Search Results
More Filters [+]

Abetimus

Alternative Names: abetimus, ljp-394, ljp394, ljp 394
Latest Update: 2015-09-01
Latest Update Note: Clinical Trial Update

Product Description

Abetimus [Abetimus sodium, LJP 394, Rentol, Riquent] is a synthetic Toleragen molecule consisting of four double-stranded oligodeoxyribonucleotides attached to nonimmunogenic polyethylene glycol, a proprietary carrier platform. Abetimus is an immunomodulating agent that induces tolerance in B cells directed against double-stranded DNA (dsDNA). It does this by cross-linking surface antibodies. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12749759/)

Mechanisms of Action: Immunosuppressive

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Innoviva
Company Location: BURLINGAME CA 94010
Company CEO: Pavel Raifeld
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Abetimus

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Lupus Erythematosus, Systemic|Lupus Nephritis|Kidney Diseases|Glomerulonephritis

Phase 2: Lupus Erythematosus, Systemic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ABETIMUS FOR LUPUS NEPHRITIS

P3

Terminated

Lupus Erythematosus, Systemic|Kidney Diseases

2011-08-16

ASPEN

P3

Terminated

Lupus Nephritis|Kidney Diseases|Lupus Erythematosus, Systemic

2009-02-01

2006-000674-73

P3

Active, not recruiting

Kidney Diseases|Lupus Erythematosus, Systemic

2008-06-02

LJP 394-90-09

P3

Completed

Lupus Nephritis|Glomerulonephritis|Lupus Erythematosus, Systemic

None

Recent News Events

Date

Type

Title